Pegaptanib sodium

• CAT Number: I045640
• CAS Number: 222716-86-1
• Molecular Weight: 50000 (Approximately)
• Purity: ≥95%

Pegaptanib sodium (Cat No.: I045640) is an RNA-based aptamer that selectively binds and inhibits vascular endothelial growth factor 165 (VEGF165), a key isoform driving abnormal blood vessel growth and leakage. It was developed as one of the first anti-VEGF therapies for neovascular (wet) age-related macular degeneration (AMD). By blocking VEGF165, pegaptanib reduces choroidal neovascularization and vision loss. Administered by intravitreal injection, it demonstrated clinical benefit, though later therapies offered broader VEGF inhibition. Pegaptanib sodium remains significant as a pioneering aptamer-based therapeutic.

Reference

[1]. Eugene W M Ng, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006 Feb;5(2):123-32.
[Content Brief]